COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F21%3A00122477" target="_blank" >RIV/00216224:14110/21:00122477 - isvavai.cz</a>
Result on the web
<a href="https://www.mdpi.com/1660-4601/18/19/10340" target="_blank" >https://www.mdpi.com/1660-4601/18/19/10340</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/ijerph181910340" target="_blank" >10.3390/ijerph181910340</a>
Alternative languages
Result language
angličtina
Original language name
COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping
Original language description
Mucormycosis, a serious and rare fungal infection, has recently been reported in COVID-19 patients worldwide. This study aims to map all the emerging evidence on the COVID-19-associated mucormycosis (CAM) with a special focus on clinical presentation, treatment modalities, and patient outcomes. An extensive literature search was performed in MEDLINE (Ovid), Embase (Ovid), Cochrane COVID-19 Study Register, and WHO COVID-19 database till 9 June 2021. The primary outcome was to summarize the clinical presentation, treatment modalities, and patient outcomes of CAM. Data were summarized using descriptive statistics and presented in tabular form. This evidence mapping was based on a total of 167 CAM patients with a mean age of 51 ± 14.62 years, and 56.28% of them were male. Diabetes mellitus (73.65% (n = 123)), hypertension (22.75% (n = 38)), and renal failure (10.77% (n = 18)) were the most common co-morbidities among CAM patients. The most common symptoms observed in CAM patients were facial pain, ptosis, proptosis, visual acuity, and vision loss. Survival was higher in patients who underwent both medical and surgical management (64.96%). Overall mortality among CAM patients was found to be 38.32%. In conclusion, this study found a high incidence of CAM with a high mortality rate. Optimal glycemic control and early identification of mucormycosis should be the priority to reduce the morbidity and mortality related to CAM.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30304 - Public and environmental health
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Environmental Research and Public Health
ISSN
1660-4601
e-ISSN
1660-4601
Volume of the periodical
18
Issue of the periodical within the volume
19
Country of publishing house
CH - SWITZERLAND
Number of pages
18
Pages from-to
1-18
UT code for WoS article
000707124900001
EID of the result in the Scopus database
2-s2.0-85116012306